Empirical use of teicoplanin versus vancomycin in febrile neutropenic patients at high risk for Gram-positive bacteraemia: results of a multi-centre prospective randomised clinical trial
Abstract number: P1764
Akan H., Korten V., Bolaman Z., Aydogdu I., Alanoglu G., Hazar V., Fen T., Gulbas Z., Akova M.
Objectives: To evaluate the efficacy and safety of empirical use of teicoplanin versus vancomycin in febrile neutropenic patients at high risk of Gram positive bacteraemia.
Methods: A total of 190 febrile neutropenic patients from 21 centres were randomised to receive teicoplanin (97 patients) or vancomycin (93 patients) in addition to a standart empirical regimen of intravenous ceftazidime and amikacin for duration of 5 to 21 days depending on response to the treatment.
Results: There was no difference between teicoplanin and vancomycin groups in terms of overall survival rates (92.5% vs. 92.6%, p > 0.05) and response rates (55.7% vs. 53.3%, p > 0.05). Gram positive isolates from peripheral blood cultures were more than Gram negative isolates (62.2%). Similar adverse events without any statistical significance occurred in both groups; most common ones being hypokalaemia, rash, diarrhoea, and hepatotoxicity. There was no difference between treatment groups according to adverse events.
Conclusion: Teicoplanin is as effective as vancomycin in terms of treatment response and overall survival rate in febrile neutropenic patients. Both antibiotics have acceptable safety profiles.
|Session name:||19th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Helsinki, Finland, 16 - 19 May 2009|
|Back to top|